Lichen Acids May Be Used as A Potential Drug For Cancer Therapy; by Inhibiting Mitochondrial Thioredoxin Reductase Purified From Rat Lung

Özgençli I., BUDAK H., Ciftci M., Anar M.

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, cilt.18, sa.11, ss.1599-1605, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18 Sayı: 11
  • Basım Tarihi: 2018
  • Doi Numarası: 10.2174/1871520618666180525095520
  • Dergi Adı: ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1599-1605
  • Anahtar Kelimeler: Thioredoxin reductase, cancer, rat lung, lichen acid, inhibition, mitochondrial TrxR.f, USNIC ACID, SECONDARY METABOLITES, MAMMALIAN THIOREDOXIN, HYPOGYMNIA-PHYSODES, LIVER THIOREDOXIN, MAJOR METABOLITES, DIFFRACTAIC ACID, CELL-LINES, ANTIOXIDANT, PURIFICATION
  • Atatürk Üniversitesi Adresli: Evet

Özet

Background: Thioredoxin reductase (E.C 1.6.4.5.; TrxR) is a widely distributed flavoprotein that catalyzes the NAI)PH-dependent reduction of thioredoxin (Trx) in many cellular events such as DNA synthesis. DNA repair, angiogenesis, antioxidative defense, and regulating apoptosis. Although TrxR is indispensible in protecting cells against oxidative stress, the overexpression of TrxR is seen in many aggressive tumors. Therefore, targeted inhibition of TrxR has been accepted as a new approach for chemotherapy.